Company Encyclopedia
View More
name
Fuan Pharmaceutical
300194.SZ
Fuan Pharmaceutical (Group) Co., Ltd., together with its subsidiaries, research and develops, produces, and sells chemical drugs in the People's Republic of China. It offers APIs; intermediates; and FFPs, such as anti-tumor, antibiotics and oral, as well as freeze-drying preparation for injection. The company was formerly known as Chongqing Fuan Pharmaceutical (Group) Co., Ltd. and changed its name to Fuan Pharmaceutical (Group) Co., Ltd.
3.159 T
300194.SZMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
PharmaceuticalsIndustry
Industry Ranking137/223
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.26%C
    • Profit Margin8.44%B
    • Gross Margin39.02%B
  • Growth ScoreE
    • Revenue YoY-35.66%E
    • Net Profit YoY-48.69%D
    • Total Assets YoY-1.21%D
    • Net Assets YoY1.14%C
  • Cash ScoreD
    • Cash Flow Margin1184.53%B
    • OCF YoY-35.66%E
  • Operating ScoreD
    • Turnover0.29D
  • Debt ScoreB
    • Gearing Ratio25.36%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Fuan Pharmaceutical released its performance for the first three quarters, with a net profit attributable to the parent company of 166 million yuan, a decrease of 44.87%

    According to the Zhitong Finance APP, Fuan Pharmaceutical released its third-quarter report for 2025. The company's operating income for the first three quarters was 1.315 billion yuan, a year-on-year decrease of 34.08%. The net profit attributable to shareholders of the listed company was 166 million yuan, a year-on-year decrease of 44.87%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 148 million yuan, a year-on-year decrease of 47.53%. The basic earnings per share were 0.14 yuan

    Zhitong·
    SZ
    300194
    -0.86%
    Zhitong·
    SZ
    300194
    -0.86%

    Fuan Pharmaceutical Announcement on the Implementation of the 2025 Half-Year Equity Distribution Plan

    Fuan Pharmaceutical Co., Ltd. announced the 2025 semi-annual equity distribution plan on September 15. A cash dividend of 0.2 yuan will be distributed for every 10 shares, with a total distribution amount of 23,794,247.64 yuan. The equity registration date is September 24, and the ex-dividend date is September 25. The distribution is for all registered shareholders, and the cash dividend will be credited on September 25

    Zhitong·
    SZ
    300194
    -0.86%
    Zhitong·
    SZ
    300194
    -0.86%

    Fuan Pharmaceutical released its performance for the first half of the year, with a net profit attributable to the parent company of 113 million yuan, a decrease of 47.74%

    According to the Zhitong Finance APP, Fuan Pharmaceutical released its semi-annual report for 2025, showing an operating income of 921 million yuan, a year-on-year decrease of 35.76%. The net profit attributable to shareholders of the listed company was 113 million yuan, a year-on-year decrease of 47.74%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 104 million yuan, a year-on-year decrease of 48.84%. The basic earnings per share were 0.1 yuan

    Zhitong·
    SZ
    300194
    -0.86%
    Zhitong·
    SZ
    300194
    -0.86%

    Asian Market Highlights: Penny Stocks To Watch In August 2025

    The Asian market is attracting attention as investors focus on penny stocks amid changing trade policies and monetary adjustments. Notable penny stocks include K. Wah International Holdings, China Shanshui Cement Group, and Fuan Pharmaceutical (Group), each with varying market caps and financial health ratings. K. Wah has a market cap of HK$7.79 billion but faces declining earnings. China Shanshui, with a market cap of HK$3.83 billion, has seen volatile prices and a recent net loss. Fuan Pharmaceutical, valued at CN¥5.85 billion, shows operational resilience despite negative earnings growth.

    Simplywall·
    HK
    00691
    -1.45%
    SZ
    300194
    -0.86%
    Simplywall·
    HK
    00691
    -1.45%
    SZ
    300194
    -0.86%

    The chemical pharmaceutical sector sees a short-term surge, with Fuan Pharmaceutical rising over 10%

    The chemical pharmaceutical sector saw a short-term surge, with Fuan Pharmaceutical rising over 10%. Yuyuan Pharmaceutical, Weier Pharmaceutical, Dezhan Health, Jingxin Pharmaceutical, and Zhendong Pharmaceutical also followed suit

    Zhitong·
    SZ
    300194
    -0.86%
    Zhitong·
    SZ
    300194
    -0.86%
    © 2025 Longbridge｜Disclaimer